One-trick pony? The Novavax logo displayed on a smartphone screen. (Budrul Chukrut/SOPA Images/LightRocket via Getty Images) ...

Novavax's stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for the year ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...

In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All ...

The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

Novavax is already poised to benefit from a separate combined Covid-flu vaccine via a deal with Sanofi announed earlier this year. Under the $1.4 billion co-licensing agreement, announced in May, ...

Novavax (NVAX) stock falls 12% in premarket as company cuts full-year revenue guidance due to a lower sales outlook for its ...